INTRODUCTION
Two types of cells, osteoblasts and osteoclasts, maintain bone homeostasis by balancing each other's function [1, 2] . Osteoblasts, which build bone, are derived from a mesenchymal progenitor cell that can also differentiate into marrow stromal cells and adipocytes [3] . Osteoclasts, originating from hemopoietic progenitors of the monocyte/macrophage lineage, immigrate into bone via the blood stream and resorb mineralized tissues [1, 2, 4] . Bone through this continuous dynamic remodeling provides structural integrity, skeletal strength, and a reservoir for hematopoiesis. Elevated osteoclast numbers and activity cause osteoporosis, Paget's disease, tumor osteolysis, various arthritis, and periodontal disease. These diseases result in low bone mass and high fracture risk, which can also occur as a result of an osteoblast defect.
To become multinucleated mature osteoclasts, mononuclear precursor cells fuse together under two critical conditions, one of which is to have an 'optimal density' of precursor cells [5] . The other is an existence of two kinds of cytokines; macrophage-colony stimulating factor (M-CSF), a survival factor, and receptor activator of NF-κB ligand (RANKL), a differentiation factor [4] . Since spleen cells and stromal cells can secrete M-CSF and RANKL, the combined of bone marrow and these cells can have the same effect compared to their treatment [6] .
Here I will provide brief description of osteoclast physiology and focus on the current understanding of the molecules affecting osteoclast differentiation. Enhanced understanding of bone biology will require reviewing the known molecular mechanisms involved in osteoclastogenesis.
OSTEOCLAST PHYSIOLOGY
To solubilize the mineral component of bone, osteoclasts form a resorption space called the sealing zone and make it into an acidic micro-environment. To do that, cytoskeleton and the integrin of osteoclast are arranged in a ring for tight attachment to the substrate [1] . αVβ3 integrin, an adhesion receptor binding the Arg-GlyAsp (RGD) motifs of matrix proteins, is essential for normal osteoclast function since mice lacking beta3 integrins fail to spread or form sealing zones, thus becoming osteosclerotic [7] . Similarly, mice deficient in src, a ubiquitously expressed non-receptor tyrosine kinase display osteopetrosis characterized by dysfunctional osteoclasts with abnormal sealing zones and αVβ3 localization [8, 9] .
Of note, αVβ3 integrin and c-Fms, the receptor of M-CSF, collaborate in the osteoclastogenic process by sharing the activation of the ERK/c-Fos, an immediate-early transcription factors in the osteoclastogenesis, signaling pathway [10] . In addition, M-CSF, the c-Fms ligand-deficient op/op mice develop severe osteopetrosis as a consequence of total absence of macrophages and osteoclasts [11, 12] .
The adherent cells are polarized and form ruffled border, which is the scaffold for large quantities of vacuolar H + -ATPase, a proton pump implicated in the acidification process of osteoclasts. The vacuolar, electrogenic H + -ATPase pumps protons across the ruffled border causing the ambient pH within the resorptive lacuna to fall and dissolving bone mineral, which is hydroxyapatite, a calciumphosphate salt, containing hydroxyl ions [13, 14] . The pH level at the ruffled border can be as low as 3 to 4.
Targeted disruption of Atp6i, a gene encoding a putative osteoclast-specific proton pump subunit (termed OC-116kD, a3, or TCIRG1), in mice results in severe osteopetrosis. Atp6i-/-osteoclast-like cells (OCLs) lose the function for extracellular acidification, but retain intracellular lysosomal proton pump activity [15, 16] .
This allows lysosomal enzymes, including cathepsin K, to cleave http://www.enm-kes.org collagen and release peptides. Cross-linked bone collagen and the peptides containing cross-links used to estimate the rate of bone resorption in serum or urine are not degraded by proteinases. A mutation in the Atp6i also causes an osteopetrosis in human [17, 18] .
Several enzymes including carbonic anhydrase II supply protons for the proton pump [19] . In resorbing osteoclasts, carbonic anhydrase II is highly expressed, whereas in nonresorbing osteoclasts only low basal expression is maintained. Antisense RNA targeted against carbonic anhydrase inhibits bone resorption in vitro [20] .
Similarly, the carbonic anhydrase inhibitor, acetozolamide can inhibit osteoclastic bone resorption [21] . Studies in patients with a congenital absence of this enzyme and osteopetrosis have shown the critical importance of carbonic anhydrase II in osteoclast [22] .
Cathepsin K, a cysteine protease, was first cloned from rabbit and human osteoclasts [23] [24] [25] . Cathepsin K knockout mice develop osteopetrosis due to a deficit matrix degradation but not demineralization [26] . Similarly, mutations in the human cathepsin K gene have demonstrated an association with a rare skeletal dysplasia, pycnodysostosis [27, 28] . Tartrate-resistant acid phosphatase (TRAP, encoded by Acp5), an osteoclast differentiation marker, as well as cathepsin K also affect the functional activity of osteoclast by regulating bone matrix resorption and collagen turnover [29] .
The CLCN7 (ClC-7gene), a widely expressed chloride transporter in osteoclast membrane, acts as a chloride-proton antiporter rather than as a chloride channel in osteoclasts [30] . Deficiency of CLCN7 in osteoclast membrane causes osteopetrosis in mice as well as in human [31] . Therefore, osteoclasts need both functional CLCN7
and vacuolar H + -ATPase in order to acidify the underlying resorption lacuna, a crucial part of the bone resorption process. Key mechanisms involved in bone resorption by osteoclasts differentiation are depicted in the Fig.1 .
Molecular Control of Osteoclast Differentiation
Prior to discussing transcription factors, it should be mentioned the regulation mechanisms of osteoclast differentiation which consists of a RANKL/RANK/OPG system (Fig. 2) http://www.enm-kes.org monocytes/macrophages including osteoclastic precursors, activated T cells, dendritic cells, and mature osteoclasts [32, 33] .
RANKL (receptor activator of NF-κB ligand), also known as TRANCE (tumor necrosis factor-related activation-induced cytokine) is a type 2 membrane protein which belongs to the TNF superfamily and is synthesized by stromal cells/osteoblasts and activated T cells [34] . Osteoprotegerin (OPG), which is related to the TNF-receptor-superfamily, is a soluble decoy receptor for RANKL and is released from bone marrow stromal cells/osteoblasts as a soluble form [35] .
By using RANK or RANKL-deficient mice showing similar osteopetrotic phenotypes, their association links their critical roles in bone remodeling [36, 37] . On the contrary, OPG competitively binds to RANKL, thereby inhibiting osteoclast differentiation. OPG knock-out mice result in osteoporosis secondary to an excess of osteoclasts [35, 38] .
The binding of RANKL to RANK stimulates the differentiation of Mouse mutants lacking transcription factors that function early in the lineage are osteopetrotic and lack either macrophages and osteoclasts or only osteoclasts. The PU.1, a myeloid-and B-cell specific transcription factor, regulates the initial stages of myeloid differentiation although it is expressed at all stages of osteoclast differentiation [39] . PU.1-/-mice exhibit osteopetrotic bone due to an arrested development of both osteoclasts and macrophages [39] .
The PU.1-/-progenitor cells fail to express the RANK as well as cFms and reconstitution of PU.1 in these cells can induce RANK expression [39, 40] . In addition, PU.1 and microphthalmia-associated transcription factor MITF, a basic helix-loop-helix-leucine zipper protein, collaborate to increase an expression of target genes like cathepsin K (Ctsk) and acid phosphatase 5 (Acp5) during osteoclast differentiation [41, 42] . They recruit p38 mitogen activated protein kinase and Nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) to target genes during osteoclast differentiation [43] .
Fos, a component of the dimeric transcription factor activator protein-1 (AP-1), is a key regulator of osteoclast-macrophage lineage determination [44] . The lack of Fos (encoding c-Fos) causes a lineage shift between osteoclasts and macrophages that results in increased numbers of bone marrow macrophages [44] . Fosl1 (encoding Fra-1) appears to be a transcriptional target of c-Fos since a transgene expressing Fra-1, a member of Fos proteins (c-Fos, FosB, Fra-1, Fra-2), rescues c-Fos-mutant mice from osteopetrosis in vivo [45] . Moreover, the rescue is both gene-dosage dependent and bone-development-specific [46] .
The pleiotropic NF-κB transcription factor is critical for osteoclast formation [47, 48] . NF-κB is a family consisting of five members:
'Rel' proteins including Rel A (p65), Rel B, and c-Rel (Rel) which synthesized as mature proteins and NF-κB1 (p105/p50) and NF-κB2 (p100/p52) which are synthesized as large precursors.
These NF-κB proteins (p105 and p100) become shorter following post-translational processing into p50 and p52, respectively. They form dimers with Rel family members.
Both the generation of NF-κB1 null mice (p50 suggesting that NFAT2 is not only indispensable but also sufficient for osteoclastogenesis [51] .
NFAT, a calcineurin-and calcium-regulated transcription factor, is a family of transcription factors originally identified in T cells. 
